Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer

NCT06014190 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06014190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06014190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2023
Completion date
December 31, 2027
Enrollment
460 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal cancer